New hope for young women with endometrial cancer: tailored treatments may save fertility
NCT ID NCT07319429
First seen Jan 11, 2026 · Last updated Jun 23, 2026 · Updated 33 times
Summary
This study aims to improve fertility-sparing treatment for young women (ages 18-45) with endometrial cancer by tailoring therapy to the tumor's genetic profile. Participants will receive either hormone therapy (progestins) or a combination with an immunotherapy drug (sintilimab), depending on their cancer subtype. The goal is to achieve complete cancer remission while preserving the uterus for future pregnancy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Shanghai Tenth People's Hospital
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, 200090, China
-
Shanghai Tenth People's Hospital
RECRUITINGShanghai, Shanghai Municipality, 200090, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sintilimab (PD-1 antibody), medroxyprogesterone acetate, megestrol acetate
What this could lead to
If successful, this could offer more effective, personalized fertility-sparing options for young women with endometrial cancer, potentially increasing response rates and preserving the uterus.
What could go wrong
This is an early-phase trial with only 260 participants, so results may not apply to all patients. Some treatments carry risks like immune-related side effects, and not all molecular subtypes may respond as expected.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.